A comparison of atenolol and nebivolol in isolated systolic hypertension

Some beta-blockers are less effective in reducing central blood pressure than other antihypertensive drugs, which may explain the higher rate of events in subjects randomized to atenolol in recent trials. We hypothesized that nebivolol, a mixed beta-blocker/nitro-vasodilator, would be more effective...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of hypertension Ročník 26; číslo 2; s. 351
Hlavní autoři:	Dhakam, Zahid, Yasmin, McEniery, Carmel M, Burton, Tim, Brown, Morris J, Wilkinson, Ian B
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Netherlands 01.02.2008
Témata:	Adrenergic beta-Antagonists - pharmacology Aged Atenolol - pharmacology Benzopyrans - pharmacology Blood Pressure - drug effects Cohort Studies Cross-Over Studies Double-Blind Method Ethanolamines - pharmacology Female Humans Hypertension - classification Hypertension - drug therapy Hypertension - physiopathology Male Middle Aged Nebivolol Pilot Projects Pulsatile Flow - drug effects Vasodilator Agents - pharmacology
ISSN:	0263-6352
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Some beta-blockers are less effective in reducing central blood pressure than other antihypertensive drugs, which may explain the higher rate of events in subjects randomized to atenolol in recent trials. We hypothesized that nebivolol, a mixed beta-blocker/nitro-vasodilator, would be more effective than atenolol in reducing central blood pressure and augmentation index (AIx). The aim of the present study was to test this in a double-blind, randomized, cross-over study, in a cohort of subjects with isolated systolic hypertension. Following a 2-week placebo run-in, 16 never-treated hypertensive subjects received atenolol (50 mg), nebivolol (5 mg) and placebo, each for 5 weeks, in a random order. Seated brachial blood pressure and heart rate were measured. Aortic blood pressure, AIx and pulse wave velocity (PWV) were assessed non-invasively. The placebo-corrected fall in brachial pressure was similar between nebivolol and atenolol, as was the reduction in PWV (mean change +/- SEM: -1.0 +/- 0.3 and -1.2 +/- 0.2 m/s; P = 0.2). However, there was less reduction in heart rate (-19 +/- 2 versus -23 +/- 2 beats/min; P < 0.01) and increase in AIx (+6 +/- 1 versus +10 +/- 1%; P = 0.04), following nebivolol. Aortic pulse pressure was significantly lower (50 +/- 2 versus 54 +/- 2 mmHg; P = 0.02) after nebivolol. N-terminal pro-B-type natriuretic peptide (proBNP) rose on both drugs (100 +/- 33 versus 75 +/- 80 pg/ml; P < 0.01 for both, NS for comparison). Nebivolol and atenolol have similar effects on brachial blood pressure and aortic stiffness. However, nebivolol reduces aortic pulse pressure more than atenolol, which may be related to a less pronounced rise in AIx and bradycardia. Whether this will translate into differences in clinical outcome requires further investigation.
AbstractList	Some beta-blockers are less effective in reducing central blood pressure than other antihypertensive drugs, which may explain the higher rate of events in subjects randomized to atenolol in recent trials. We hypothesized that nebivolol, a mixed beta-blocker/nitro-vasodilator, would be more effective than atenolol in reducing central blood pressure and augmentation index (AIx). The aim of the present study was to test this in a double-blind, randomized, cross-over study, in a cohort of subjects with isolated systolic hypertension.OBJECTIVESSome beta-blockers are less effective in reducing central blood pressure than other antihypertensive drugs, which may explain the higher rate of events in subjects randomized to atenolol in recent trials. We hypothesized that nebivolol, a mixed beta-blocker/nitro-vasodilator, would be more effective than atenolol in reducing central blood pressure and augmentation index (AIx). The aim of the present study was to test this in a double-blind, randomized, cross-over study, in a cohort of subjects with isolated systolic hypertension.Following a 2-week placebo run-in, 16 never-treated hypertensive subjects received atenolol (50 mg), nebivolol (5 mg) and placebo, each for 5 weeks, in a random order. Seated brachial blood pressure and heart rate were measured. Aortic blood pressure, AIx and pulse wave velocity (PWV) were assessed non-invasively.METHODSFollowing a 2-week placebo run-in, 16 never-treated hypertensive subjects received atenolol (50 mg), nebivolol (5 mg) and placebo, each for 5 weeks, in a random order. Seated brachial blood pressure and heart rate were measured. Aortic blood pressure, AIx and pulse wave velocity (PWV) were assessed non-invasively.The placebo-corrected fall in brachial pressure was similar between nebivolol and atenolol, as was the reduction in PWV (mean change +/- SEM: -1.0 +/- 0.3 and -1.2 +/- 0.2 m/s; P = 0.2). However, there was less reduction in heart rate (-19 +/- 2 versus -23 +/- 2 beats/min; P < 0.01) and increase in AIx (+6 +/- 1 versus +10 +/- 1%; P = 0.04), following nebivolol. Aortic pulse pressure was significantly lower (50 +/- 2 versus 54 +/- 2 mmHg; P = 0.02) after nebivolol. N-terminal pro-B-type natriuretic peptide (proBNP) rose on both drugs (100 +/- 33 versus 75 +/- 80 pg/ml; P < 0.01 for both, NS for comparison).RESULTSThe placebo-corrected fall in brachial pressure was similar between nebivolol and atenolol, as was the reduction in PWV (mean change +/- SEM: -1.0 +/- 0.3 and -1.2 +/- 0.2 m/s; P = 0.2). However, there was less reduction in heart rate (-19 +/- 2 versus -23 +/- 2 beats/min; P < 0.01) and increase in AIx (+6 +/- 1 versus +10 +/- 1%; P = 0.04), following nebivolol. Aortic pulse pressure was significantly lower (50 +/- 2 versus 54 +/- 2 mmHg; P = 0.02) after nebivolol. N-terminal pro-B-type natriuretic peptide (proBNP) rose on both drugs (100 +/- 33 versus 75 +/- 80 pg/ml; P < 0.01 for both, NS for comparison).Nebivolol and atenolol have similar effects on brachial blood pressure and aortic stiffness. However, nebivolol reduces aortic pulse pressure more than atenolol, which may be related to a less pronounced rise in AIx and bradycardia. Whether this will translate into differences in clinical outcome requires further investigation.CONCLUSIONSNebivolol and atenolol have similar effects on brachial blood pressure and aortic stiffness. However, nebivolol reduces aortic pulse pressure more than atenolol, which may be related to a less pronounced rise in AIx and bradycardia. Whether this will translate into differences in clinical outcome requires further investigation. Some beta-blockers are less effective in reducing central blood pressure than other antihypertensive drugs, which may explain the higher rate of events in subjects randomized to atenolol in recent trials. We hypothesized that nebivolol, a mixed beta-blocker/nitro-vasodilator, would be more effective than atenolol in reducing central blood pressure and augmentation index (AIx). The aim of the present study was to test this in a double-blind, randomized, cross-over study, in a cohort of subjects with isolated systolic hypertension. Following a 2-week placebo run-in, 16 never-treated hypertensive subjects received atenolol (50 mg), nebivolol (5 mg) and placebo, each for 5 weeks, in a random order. Seated brachial blood pressure and heart rate were measured. Aortic blood pressure, AIx and pulse wave velocity (PWV) were assessed non-invasively. The placebo-corrected fall in brachial pressure was similar between nebivolol and atenolol, as was the reduction in PWV (mean change +/- SEM: -1.0 +/- 0.3 and -1.2 +/- 0.2 m/s; P = 0.2). However, there was less reduction in heart rate (-19 +/- 2 versus -23 +/- 2 beats/min; P < 0.01) and increase in AIx (+6 +/- 1 versus +10 +/- 1%; P = 0.04), following nebivolol. Aortic pulse pressure was significantly lower (50 +/- 2 versus 54 +/- 2 mmHg; P = 0.02) after nebivolol. N-terminal pro-B-type natriuretic peptide (proBNP) rose on both drugs (100 +/- 33 versus 75 +/- 80 pg/ml; P < 0.01 for both, NS for comparison). Nebivolol and atenolol have similar effects on brachial blood pressure and aortic stiffness. However, nebivolol reduces aortic pulse pressure more than atenolol, which may be related to a less pronounced rise in AIx and bradycardia. Whether this will translate into differences in clinical outcome requires further investigation.
Author	Brown, Morris J Wilkinson, Ian B Yasmin McEniery, Carmel M Burton, Tim Dhakam, Zahid
Author_xml	– sequence: 1 givenname: Zahid surname: Dhakam fullname: Dhakam, Zahid organization: Clinical Pharmacology Unit, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 2QQ, UK – sequence: 2 surname: Yasmin fullname: Yasmin – sequence: 3 givenname: Carmel M surname: McEniery fullname: McEniery, Carmel M – sequence: 4 givenname: Tim surname: Burton fullname: Burton, Tim – sequence: 5 givenname: Morris J surname: Brown fullname: Brown, Morris J – sequence: 6 givenname: Ian B surname: Wilkinson fullname: Wilkinson, Ian B
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/18192850$$D View this record in MEDLINE/PubMed
BookMark	eNo1kEtLxDAUhbMYcR76D0Syctcxj2mbLIdBrTLgRtclSW8wkia1aYX59wYdV5fD-Tjw3TVahBgAoRtKtpTI-r55abZEE8qBM8EsE9zIBVoRVvGi4iVbonVKn4QQIWt-iZZUUMlESVao2WMT-0GNLsWAo8VqghB99FiFDgfQ7vs3uYAz4XPb4XRKU_TO4I_TAGPmk4vhCl1Y5RNcn-8GvT8-vB2a4vj69HzYHwuzI3QqOFSCMltRCUpIbRhnldpZLYy0mthdqUFnDV2zqu5AccOt0NLI7NWV1hi2QXd_u8MYv2ZIU9u7ZMB7FSDOqa0Jy3_gNIO3Z3DWPXTtMLpejaf23539AHxGXmM
CitedBy_id	crossref_primary_10_1097_MBP_0b013e32833c8a64 crossref_primary_10_1097_HJH_0000000000000014 crossref_primary_10_1111_jch_14616 crossref_primary_10_1093_ajh_hpv134 crossref_primary_10_1007_s11906_009_0043_4 crossref_primary_10_1007_s00392_018_1287_2 crossref_primary_10_1111_j_1751_7176_2009_00140_x crossref_primary_10_1159_000443615 crossref_primary_10_1016_j_jfma_2024_09_023 crossref_primary_10_1002_clc_20841 crossref_primary_10_2165_11599040_000000000_00000 crossref_primary_10_1177_1358863X15569868 crossref_primary_10_21518_2307_1109_2016_2 crossref_primary_10_1111_bcpt_13248 crossref_primary_10_1161_HYPERTENSIONAHA_109_144808 crossref_primary_10_1111_jch_13758 crossref_primary_10_1097_HJH_0b013e32835e8f5b crossref_primary_10_1111_j_1365_2125_2012_04342_x crossref_primary_10_1007_s00421_016_3392_0 crossref_primary_10_1093_cvr_cvp236 crossref_primary_10_1016_j_ancard_2010_05_004 crossref_primary_10_1016_j_ijcard_2016_05_017 crossref_primary_10_1093_eurheartj_eht565 crossref_primary_10_1097_HJH_0b013e32835a8eca crossref_primary_10_1016_j_atherosclerosis_2015_05_007 crossref_primary_10_1517_14656566_2015_1020790 crossref_primary_10_3109_10641963_2014_960972 crossref_primary_10_1161_HYPERTENSIONAHA_109_134379 crossref_primary_10_1038_jhh_2011_28 crossref_primary_10_1007_s10237_017_0871_0 crossref_primary_10_1016_j_nephro_2016_01_011 crossref_primary_10_1038_ajh_2009_195 crossref_primary_10_7759_cureus_34965 crossref_primary_10_1002_14651858_CD007451_pub2 crossref_primary_10_1111_j_1755_5922_2012_00321_x crossref_primary_10_1097_HJH_0000000000002334 crossref_primary_10_1038_ajh_2008_156 crossref_primary_10_1007_s11892_010_0100_z crossref_primary_10_1097_HJH_0b013e328333146d crossref_primary_10_1016_j_jash_2014_12_013 crossref_primary_10_1038_hr_2012_143 crossref_primary_10_1161_HYPERTENSIONAHA_111_172908 crossref_primary_10_1136_heartasia_2015_010656 crossref_primary_10_1111_j_1365_2125_2012_04203_x crossref_primary_10_1161_HYPERTENSIONAHA_109_133116 crossref_primary_10_1016_j_cjca_2014_03_010 crossref_primary_10_2217_fca_14_51 crossref_primary_10_1111_jch_13234 crossref_primary_10_1111_jch_14323 crossref_primary_10_1038_nrcardio_2010_96 crossref_primary_10_2165_11530710_000000000_00000 crossref_primary_10_1016_j_cjca_2013_12_001 crossref_primary_10_1007_s00059_012_3695_9 crossref_primary_10_1016_j_acvd_2013_11_003 crossref_primary_10_2991_artres_k_200711_001 crossref_primary_10_1007_s40292_018_0286_8 crossref_primary_10_1093_ajh_hpaa187 crossref_primary_10_1016_j_cger_2009_06_001 crossref_primary_10_1097_01_hjh_0000431740_32696_cc crossref_primary_10_1093_ajh_hpt124 crossref_primary_10_1517_14656566_2010_496452 crossref_primary_10_2165_11593790_000000000_00000 crossref_primary_10_1016_j_jacc_2009_02_088 crossref_primary_10_1016_j_hipert_2011_11_002 crossref_primary_10_1177_1753944709346519 crossref_primary_10_1371_journal_pone_0072102 crossref_primary_10_1016_j_cjca_2014_03_003 crossref_primary_10_1097_HJH_0000000000002199 crossref_primary_10_1161_HYPERTENSIONAHA_110_155507 crossref_primary_10_1161_HYPERTENSIONAHA_121_17579 crossref_primary_10_1007_s11906_016_0686_x crossref_primary_10_1016_j_ihj_2018_10_418 crossref_primary_10_1016_j_lpm_2011_01_030 crossref_primary_10_1161_HYPERTENSIONAHA_109_148999 crossref_primary_10_1093_ajh_hpu245 crossref_primary_10_1097_HCO_0b013e32832c129c crossref_primary_10_1371_journal_pone_0088722 crossref_primary_10_1007_s10354_009_0650_3 crossref_primary_10_1586_14779072_2016_1167598 crossref_primary_10_1097_JIM_0000000000000159 crossref_primary_10_1007_s40256_020_00422_0 crossref_primary_10_1093_ajh_hpu082 crossref_primary_10_1016_j_jash_2013_09_001 crossref_primary_10_1097_HJH_0b013e328346a583 crossref_primary_10_1152_japplphysiol_00405_2017 crossref_primary_10_1097_HJH_0b013e328364fbca crossref_primary_10_1097_HJH_0b013e3283442f37 crossref_primary_10_1097_HJH_0000000000001412 crossref_primary_10_3810_hp_2010_11_345 crossref_primary_10_1016_j_amjmed_2010_04_012 crossref_primary_10_1097_MD_0000000000006290 crossref_primary_10_2217_fca_2020_0079 crossref_primary_10_1016_j_amjmed_2010_04_014 crossref_primary_10_1016_j_jash_2015_02_013 crossref_primary_10_1097_FJC_0000000000000647 crossref_primary_10_1016_j_vph_2015_06_004 crossref_primary_10_1161_HYPERTENSIONAHA_109_131466 crossref_primary_10_1007_s12170_015_0438_5 crossref_primary_10_1016_j_ijcard_2016_06_150 crossref_primary_10_1016_j_jash_2016_11_007 crossref_primary_10_1007_s15006_012_1144_6 crossref_primary_10_1007_s40265_015_0435_5 crossref_primary_10_1016_j_jacc_2008_12_076 crossref_primary_10_1007_s40265_016_0642_8 crossref_primary_10_1007_s11906_008_0061_7 crossref_primary_10_1093_ajh_hpaf098 crossref_primary_10_1093_eurheartj_eht151 crossref_primary_10_1111_jch_13312 crossref_primary_10_1161_HYPERTENSIONAHA_115_06467 crossref_primary_10_1111_bcpt_12771 crossref_primary_10_1111_j_1475_097X_2009_00856_x crossref_primary_10_1093_ajh_hps074 crossref_primary_10_1161_HYPERTENSIONAHA_111_182337 crossref_primary_10_1097_HJH_0b013e32832ea925 crossref_primary_10_1093_ajh_hpu135 crossref_primary_10_1038_jhh_2017_26 crossref_primary_10_1097_HJH_0b013e32830dd0b0 crossref_primary_10_1007_s11255_013_0431_1 crossref_primary_10_1038_jhh_2008_43 crossref_primary_10_1016_j_jash_2015_10_012 crossref_primary_10_1161_HYPERTENSIONAHA_116_07250 crossref_primary_10_1007_s10557_021_07205_y crossref_primary_10_1111_jch_12210 crossref_primary_10_1177_1753944713513062
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1097/HJH.0b013e3282f283c9
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
ExternalDocumentID	18192850
Genre	Randomized Controlled Trial Journal Article Comparative Study
GrantInformation_xml	– fundername: British Heart Foundation grantid: FS/07/001/21990
GroupedDBID	--- .-D .55 .GJ .XZ .Z2 01R 0R~ 1J1 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 71W 77Y 7O~ AAAAV AAAXR AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AAQKA AARTV AASCR AASOK AAUEB AAWTL AAXQO AAYEP ABASU ABBUW ABDIG ABJNI ABOCM ABPXF ABVCZ ABXVJ ABXYN ABZAD ABZZY ACCJW ACDDN ACDOF ACEWG ACGFO ACGFS ACILI ACLDA ACWDW ACWRI ACXJB ACXNZ ACZKN ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEBDS AEETU AENEX AFBFQ AFDTB AFEXH AFFNX AFMBP AFNMH AFSOK AFUWQ AGINI AHOMT AHQNM AHQVU AHRYX AHVBC AI. AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BOYCO BQLVK BS7 C45 CAG CGR COF CS3 CUY CVF DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- FW0 GNXGY GQDEL H0~ HLJTE HZ~ IKREB IKYAY IN~ IPNFZ JF9 JG8 JK3 JK8 K8S KD2 KMI L-C L7B N9A NPM N~7 N~B N~M O9- OAG OAH OCUKA ODA ODMTH OHYEH OL1 OLG OLH OLU OLV OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OVOZU OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P R58 RIG RLZ S4R S4S T8P TEORI TSPGW V2I VH1 VVN W3M WOQ WOW X3V X3W X7M XXN XYM YFH YYP ZFV ZGI ZXP ZZMQN 7X8 ADKSD
ID	FETCH-LOGICAL-c401t-3e6812f619ea89bc2326a4fb8c9fb0f45beb13eb7267dea3c3f8b9c9328d5fcc2
IEDL.DBID	7X8
ISICitedReferencesCount	162
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000252778100028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0263-6352
IngestDate	Mon Sep 08 17:30:41 EDT 2025 Fri May 30 11:01:08 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	2
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c401t-3e6812f619ea89bc2326a4fb8c9fb0f45beb13eb7267dea3c3f8b9c9328d5fcc2
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
PMID	18192850
PQID	70201331
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_70201331 pubmed_primary_18192850
PublicationCentury	2000
PublicationDate	2008-02-01
PublicationDateYYYYMMDD	2008-02-01
PublicationDate_xml	– month: 02 year: 2008 text: 2008-02-01 day: 01
PublicationDecade	2000
PublicationPlace	Netherlands
PublicationPlace_xml	– name: Netherlands
PublicationTitle	Journal of hypertension
PublicationTitleAlternate	J Hypertens
PublicationYear	2008
SSID	ssj0008973
Score	2.321851
Snippet	Some beta-blockers are less effective in reducing central blood pressure than other antihypertensive drugs, which may explain the higher rate of events in...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	351
SubjectTerms	Adrenergic beta-Antagonists - pharmacology Aged Atenolol - pharmacology Benzopyrans - pharmacology Blood Pressure - drug effects Cohort Studies Cross-Over Studies Double-Blind Method Ethanolamines - pharmacology Female Humans Hypertension - classification Hypertension - drug therapy Hypertension - physiopathology Male Middle Aged Nebivolol Pilot Projects Pulsatile Flow - drug effects Vasodilator Agents - pharmacology
Title	A comparison of atenolol and nebivolol in isolated systolic hypertension
URI	https://www.ncbi.nlm.nih.gov/pubmed/18192850 https://www.proquest.com/docview/70201331
Volume	26
WOSCitedRecordID	wos000252778100028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB6qFfHi-1Gfe_AamnaTzS4IUsQShJYeFHoLu5tdLJRNbWt_v7N56E0PQgiEJCQMszPfPPYbgPtIaBZx5mMTyYPI9GjADfP0eIwyxmXCdF4Om0jGYz6dikkLHpq9ML6tsrGJpaHOC-1z5N0EcQ3GU73HxUfgZ0b52mo9QGML2hSBjNfpZPrDFc5FVV_GrwboVvvNxjmRdNOXtMkAYshh0cXqXyBm6WqGB__7yUPYryEmGVQ6cQQt445hd1QX0U8gHRD9PX2QFJYg3PTZ9TmRLifOqNmmvJo5gk_M8W5OPOGzZxAm7xi3Lsuu98Kdwtvw-fUpDeqBCoHGMGodUOPZxizGTEZyoTSiKSYjq7gWVoU2ihVabmpU0mdJbiTV1HIlNEI8nsdW6_4ZbLvCmQsguaEilCKyeOCy73HDGYskD1WcUypoB-4aCWWosL4KIZ0pPldZI6MOnFdCzhYVr0bW8-RsPA4v_3z3Cvaqvg3fVnINbYtL1dzAjt6sZ6vlbakHeB5PRl_q9ryC
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+comparison+of+atenolol+and+nebivolol+in+isolated+systolic+hypertension&rft.jtitle=Journal+of+hypertension&rft.au=Dhakam%2C+Zahid&rft.au=McEniery%2C+Carmel+M&rft.au=Burton%2C+Tim&rft.au=Brown%2C+Morris+J&rft.date=2008-02-01&rft.issn=0263-6352&rft.volume=26&rft.issue=2&rft.spage=351&rft_id=info:doi/10.1097%2FHJH.0b013e3282f283c9&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0263-6352&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0263-6352&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0263-6352&client=summon